Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

11241. A 5-year controlled study of B.C.G. and radiotherapy inoperable lung cancer. (PubMed)

A 5-year controlled study of B.C.G. and radiotherapy inoperable lung cancer. Forty-eight patients with advanced squamous-cell lung cancer were treated with radical radiotherapy. Thereafter twenty-five received B.C.G. regularly and twenty-three did not. Differences in survival during the first year of observation and absence of peripheral metastases were significantly in favour of the patients treated with B.C.G. There was no response to B.C.G. in patients receiving palliative radiotherapy

1976 Lancet

11242. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. (PubMed)

1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. Prolonged 1-phenylalanine mustard (L-PAM) administration as an adjuvant to mastectomy in the management of patients with primary breast cancer and pathologically positive axillary nodes was evaluated by a prospective, randomized, clinical trial. Treatment failures occurred in 22 per cent of 108 patients receiving placebo and 9.7 per cent of 103 women given L-PAM (p = 0.01). A statistically (...) has been demonstrated to be effective in the treatment of women with primary breast cancer, particularly those who are premenopausal. Results were achieved with minimal undesirable side effects.

1975 NEJM

11243. Comparison of 5-day, 1-day, and 2-day cyclical combination chemotherapy in advanced breast cancer. (PubMed)

Comparison of 5-day, 1-day, and 2-day cyclical combination chemotherapy in advanced breast cancer. The results of 5-day cyclical combined chemotherapy for advanced breast cancer were compared in two trials with the less demanding 1-day and 2-day regimens. At all stages, except at 3 months, 5-day treatment was significantly more successful in providing regression and remission of tumours than the 1-day regimen. However, although the differences are not statistically significant, data from

1975 Lancet

11244. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. (PubMed)

Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. Anecdotal accounts suggested that smoking marihuana decreases the nausea and vomiting associated with cancer chemotherapeutic agents. Oral delta-9-tetrahydrocannabinol was compared with placebo in a controlled, randomized, "double-blind" experiment. All patients were receiving chemotherapeutic drugs known to cause nausea and vomiting of central origin. Each patient was to serve as his own control

1975 NEJM

11245. Gram-negative infections in cancer. Study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin. (PubMed)

Gram-negative infections in cancer. Study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin. 4202683 1974 02 11 2016 10 17 0098-7484 227 1 1974 Jan 07 JAMA JAMA Gram-negative infections in cancer. Study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin. 45-8 Klastersky J J Henri A A Hensgens C C Daneau D D eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0

1974 JAMA

11246. Pseudomonas aeruginosa vaccine in cancer patients. (PubMed)

Pseudomonas aeruginosa vaccine in cancer patients. 4201225 1974 01 05 2006 11 15 0003-4819 79 4 1973 Oct Annals of internal medicine Ann. Intern. Med. Pseudomonas aeruginosa vaccine in cancer patients. 518-27 Young L S LS Meyer R D RD Armstrong D D eng Clinical Trial Journal Article Randomized Controlled Trial United States Ann Intern Med 0372351 0003-4819 0 Antibodies, Bacterial 0 Bacterial Vaccines AIM IM Adult Antibodies, Bacterial analysis Bacterial Vaccines Humans Immunization Schedule

1974 Annals of Internal Medicine

11247. Evaluation of periodic breast cancer screening with mammography. Methodology and early observations. (PubMed)

Evaluation of periodic breast cancer screening with mammography. Methodology and early observations. 5951878 1966 04 09 2016 10 17 0098-7484 195 9 1966 Feb 28 JAMA JAMA Evaluation of periodic breast cancer screening with mammography. Methodology and early observations. 731-8 Shapiro S S Strax P P Venet L L eng Clinical Trial Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 AIM IM Adult Biopsy Breast Neoplasms diagnosis epidemiology Connecticut Female Follow-Up

1966 JAMA